Li Bang Pharmaceutical-B (09637.HK) expects a profit: revenue soared over 7 times in the first half of the year, losses significantly narrowed, and growth potential is attracting attention.

According to the Zhitong Finance APP, on August 6th after trading hours, Li Bang Pharmaceutical-B (09637.HK) released a positive profit forecast announcement, disclosing its unaudited financial performance for the six months ending June 30, 2026. During the reporting period, the group expects to record revenue of approximately RMB 103 million to RMB 106 million, a significant increase of about 750% to 775% compared to RMB 12.1 million in the same period last year; the loss for the period is expected to be approximately RMB 158 million to RMB 178 million, a reduction of about 15% to 25% compared to approximately RMB 210 million in the same period last year.